Early initiation of heparin therapy for treatment of stroke is not only associated with an improved outcome, but also with the risk of hemorrhagic transformation. We compared the efficacy of three unfractionated heparin bolus regimens (0 U/kg, 30 U/kg, or 80 U/kg) in achieving a therapeutic activated partial thromboplastin time over the first 6-hour period in a cohort of 54 patients admitted with transient ischemic attack or stroke. Patients treated with the low bolus dose (30 U/kg) were more often within the therapeutic range for activated partial thromboplastin time at two hours after the initial bolus than patients treated with the other regimens. The percentage of therapeutic activated partial thromboplastin time results within the first six hours of treatment was greater in the group treated with the low bolus dose. Using the low bolus dose may reduce complication rates and improve clinical outcomes in the future clinical trials.
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Keywords: anticoagulation; unfractionated heparin; stroke; transient ischemic attack; bolus U nfractionated heparin ðUFHÞ is effective for the treatment of venous thromboembolism and acute coronary syndromes. 1 The use of intravenous UFH for patients with acute ischemic stroke has been an area of longstanding controversy. 2, 3 Recent guidelines indicate that most stroke patients do not need emergency administration of anticoagulants such as UFH. 3 Unfortunately, randomized trials have not adequately studied UFH in patients with conditions likely to respond to this treatment. 4, 5 The reported trials lumped patients with ischemic stroke together, without diagnostic investigations defining etiology, stroke subtypes, or vascular lesions. Therefore, many neurologists continue to believe in the efficacy of UFH in specific stroke syndromes such as arterial dissection, cardioembolic stroke, hypercoagulability, and crescendo transient ischemic attack ðTIAÞ. 2, 6, 7 A total of 88% of neurologists in the United States and 84% of neurologists in Canada use intravenous UFH for acute stroke patients with atrial fibrillation; 27% of ischemic stroke patients in Germany and 42.5% of ischemic stroke patients in the Republic of Korea receive intravenous UFH therapy. [6] [7] [8] A recent study revealed that reducing the interval from the onset of stroke to the initiation of UFH treatment can improve the chances of efficacy. 9 Reducing the interval from the onset of stroke to therapeutic anticoagulation may improve the chances of efficacy much more. However, previous reports implicated early initiation of UFH treatment and excessive anticoagulation as special risk factors for brain hemorrhage. 10, 11 Brain hemorrhage, which is the most feared complication of early anticoagulation therapy in patients with ischemic stroke, is associated with supratherapeutic anticoagulation, whereas stroke recurrence is related to subtherapeutic anticoagulation. Therefore, a method for controlling the degree of anticoagulation to avoid subtherapeutic and supratherapeutic anticoagulation in the hyperacute stage would be beneficial to patients requiring intravenous UFH treatment.
Previous studies evaluating dosing protocols for intravenous UFH therapy started an activated partial thromboplastin time ðAPTTÞ measurement 6 hours after the initial UFH bolus. [12] [13] [14] We do not know an UFH bolus dose that is effective in rapidly attaining a therapeutic APTT over the first 6-hour period. We compared the efficacy of 3 UFH bolus regimens in achieving a therapeutic APTT within 6 hours in a randomized prospective cohort of 54 patients admitted with TIA or acute stroke.
Patients and Methods

Patients
All patients enrolled in the study were admitted with a diagnosis of TIA or acute stroke to the emergency department at Seoul National University Hospital, Seoul, Republic of Korea, between June 2002 and November 2002.
Inclusion criteria for enrollment consisted of the following: ð1Þ admission within the first 48 hours of the onset of an acute neurologic deficit suspected as TIA or stroke ðcounted from the time of awakening, if the symptoms had been noted on wakening from sleepÞ and ð2Þ anticoagulation required for TIA or stroke because of suspected or known embolic source, stroke in evolution ðstroke with progressing symp-tomsÞ, crescendo TIA, failure of antiplatelet therapy for prophylaxis of stroke, or cerebral venous sinus thrombosis.
Exclusion criteria for enrollment consisted of the following: ð1Þ age >80 years; ð2Þ thrombolytic or anticoagulant therapy in the last 24 hours; ð3Þ current active hemorrhage, either cerebral or otherwise; ð4Þ history of hemorrhoids, peptic ulcer, or recent major surgery; ð5Þ history of UFH-related complications and/or allergy; ð6Þ lack of informed consent; ð7Þ pregnancy or breast-feeding; or ð8Þ an abnormal basal APTT.
All patients enrolled were required to give informed consent. If for some reason a patient was unable to give consent, a first-degree relative was required to give consent. Randomization of the bolus dose was performed with random allocation through a predeveloped envelope system, with envelopes opened by the enrolling physicians. Allocation concealment was maintained until the clinical decision to use UFH therapy was made, after inclusion criteria were met and complete consent was obtained. Patients, but not physicians or nurses, were blinded to the bolus dose.
Baseline data collected for each patient included age, gender, body weight, indication for heparin use, a baseline APTT, and medical history ðeg, hypertension, diabetes, and hypercholesterolemiaÞ.
The study protocol was approved by the ethics committee of the Seoul National University Hospital.
Treatment
Patients were randomly allocated to 1 of the 3 bolus doses ð0, 30, or 80 U/kgÞ. Group 1 patients received no bolus of UFH ðChoongwae Pharma, Seoul, Republic of KoreaÞ; group 2 patients, a bolus of 30 U/kg; and group 3 patients, a bolus of 80 U/kg. The bolus dose of 0 U/kg represents the regimen used by some neurologists who would not use an UFH bolus in stroke patients for fear of hemorrhagic transformation. 14 The bolus dose of 30 U/kg was chosen because our small pilot study showed that this dose achieved a therapeutic APTT rapidly, while avoiding supratherapeutic and subtherapeutic anticoagulation. The bolus dose of 80 U/kg represents the regimen used to treat venous thromboembolism. 1 The initial infusion rate of intravenous UFH was 17.5 U/kg per hour, which represents the dosing regimen used to treat venous thromboembolism. 1 The infusion was started immediately after the bolus. Activated partial thromboplastin times were obtained at 2 and 4 hours after the initiation of intravenous UFH therapy without dosage adjustment. After an APTT was obtained at 6 hours, the infusion rate was corrected by a weight-based nomogram. After then, APTTs were obtained every 6 hours and adjusted by the nomogram.
Nonstudy medications, such as antihypertensive agents and osmotic diuretics were allowed, while the use of other antithrombotic agents such as aspirin or clopidogrel was prohibited during UFH treatment, even in those who were on chronic treatment with aspirin or clopidogrel. Aspirin ð300 mg dailyÞ, clopidogrel ð75 mg dailyÞ, or warfarin ða loading dose of 5 to 10 mg dailyÞ was given to the patients who completed UFH treatment.
The APTT was determined with the STA-PTT Automate 5 reagent ðDiagnostica Stago, Asnieres, FranceÞ. A normal APTT range was 29 to 45 seconds, and a therapeutic APTT range was defined as 84 to 136 seconds, equivalent to an anti-Xa activity range of 0.3 to 0.7 U/mL, which is a gold standard for monitoring UFH treatment. 8 The success rates were calculated as the proportion of therapeutic APTT results of the total number of APTT measurements performed at that time point. The incidence of UFH-related complications, including hemorrhagic events, thrombocytopenia, elevated liver enzymes, skin necrosis, allergy, alopecia, and hypoaldosteronism, was recorded during heparinization.
Statistical Analysis
For continuous variables, differences between groups were evaluated with a 1-way analysis of variance ðANOVAÞ. For dichotomous variables, the 2 test or the Fisher exact test was used. A P value <.05 was considered statistically significant. The APTT values were capped at 160 seconds for statistical analysis because our laboratory reported the highest APTTs as >160 seconds. SPSS for Windows software ðRelease 12.0.1Þ was used for the statistical analysis.
Results
Between June 2002 and November 2002, 80 patients met the inclusion criteria. A total of 19 patients were excluded from the study because of the concurrent use of thrombolytic drugs or warfarin. Six patients were excluded because of abnormal basal APTTs. One patient declined to participate. Thus, a total of 54 patients were enrolled.
The most frequent indications for UFH use were treatment of embolic stroke and crescendo TIA ðTable 1Þ. Demographic and clinical features were similar among the 3 groups ðTable 2Þ. The mean time between symptom onset and presentation to the emergency department was 21.8 + 19.6 hours. Figure 1 shows the mean + standard deviation APTT results during the first 6 hours of UFH therapy according to the UFH dosing regiments.
The success rate was higher in group 2 ð61.1%Þ compared to both group 1 ð5.6%, P < .001Þ and group 3 ð0%, P < .001Þ on the initial APTT ðFigure 2AÞ; there was a significantly higher proportion of patients above the therapeutic range in group 3 ð100%Þ compared to both group 1 ð0%, P < .001Þ and group 2 ð22.2%, P < .001Þ; there was a significantly higher proportion of patients below the therapeutic range in group 1 ð94.4%Þ compared to both group 2 ð16.7%, P < .001Þ and group 3 ð0%, P < .001Þ.
At 4 hours, the success rates of group 1 ð38.9%, P ¼ .041Þ and group 2 ð50%, P ¼ .007Þ were higher than the success rate of group 3 ð5.6%; Figure 2BÞ . There was a significantly higher proportion of patients above the therapeutic range in group 3 ð88.9%Þ compared to both group 1 ð11.1%, P < .001Þ and group 2 ð38.9%, P ¼ .005Þ; there was a significantly higher proportion of patients below the therapeutic range in group 1 ð50%Þ compared to both group 2 ð11.1%, P ¼ .027Þ and group 3 ð5.6%, P ¼ .007Þ. At 6 hours, the success rates of group 1 ð66.7%, P < .001Þ and group 2 ð61.1%, P ¼ .001Þ were higher than the success rate of group 3 ð5.6%; Figure 2CÞ . There was a significantly higher proportion of patients above the therapeutic range in group 3 ð88.9%Þ compared to both group 1 ð11.1%, P < .001Þ and group 2 ð33.3%, P ¼ .002Þ.
The 3 groups were also compared with respect to their total results from APTT testing within the initial 6 hours of treatment. The success rate was significantly higher in group 2 ð57.4%Þ than in both group 1 ð37%, P ¼ .034Þ and group 3 ð3.7%, P < .001; Figure 2DÞ .
One group 2 patient, who had a left middle cerebral artery infarction, developed a cerebellar hemorrhage 3 days after starting UFH. It was a nonfatal hemorrhage with symptoms of nausea, vomiting, and gait disturbance, which improved during the following 2 weeks. Other UFH-related complications were not reported. Differences in complication rates among the 3 groups were not significant ðP > .05Þ. 
Discussion
Our study shows that the use of a UFH bolus of 30 U/kg is more effective in rapidly attaining therapeutic APTTs 2 hours after the start of intravenous UFH therapy than the other bolus regimens.
Patients treated with the bolus of 30 U/kg also had a significantly greater proportion of therapeutic APTTs over the first 6-hour period. The use of UFH dosing regimens has mostly been studied in internal medicine. 12, 13 A UFH bolus of 80 U/kg and infusion of 18 U/kg per hour are recommended for venous thromboembolism, whereas an initial bolus of 60 to 70 U/kg and initial infusion of 12 to 15 U/kg per hour are recommended for unstable angina and non-ST-segment elevation myocardial infarction. 1 In contrast, few dosing regimens have been validated for TIA or stroke, although Canadian neurologists attempted to validate the use of a nomogram for UFH dosing in these conditions. 14 Doses of UFH administered to treat patients with TIA or stroke were lower than those typically used to treat patients with venous thromboembolism or acute coronary syndromes.
Furthermore, while the role of UFH is clearly established in the treatment of venous thromboembolism and acute coronary syndromes, anticoagulation with parenteral UFH for acute ischemic stroke remains an area of ongoing controversy with both strong proponents and critics. [1] [2] [3] Unfavorable information on UFH use could have arisen from limitations of the methods used in the previous studies. 4, 5, 15 One limitation is long intervals allowed by the studies from the onset of stroke to the initiation of treatment. 4, 5, 15 In these studies, the time from stroke to initiation of treatment was up to 12 hours 4 or 48 hours. 5, 15 One randomized, controlled trial suggested that an anticoagulant regimen of intravenous UFH, administered within the first 3 hours of the onset of symptoms, could be beneficial to patients with an acute hemispheric cerebral infarction. 9 Patients treated with UFH were more likely to be self-independent at 90 days after stroke. If reducing the interval from the onset of stroke to the initiation of UFH treatment can improve the chances of efficacy, reducing the interval from the onset of stroke to therapeutic anticoagulation may improve the chances of efficacy much more.
Another limitation is that the results of an aggregate group cannot confidently be applied to any specific subgroup. 4, 5 Some stroke patients may carry a sufficiently high risk of recurrence to justify the risks of UFH anticoagulation, but the problem lies in identifying these patients. One subgroup of patients widely thought to benefit from judicious use of intravenous UFH is the subgroup at risk for cardiogenic emboli. 2 A double-blind, multicenter study of low-molecular-weight heparin in acute ischemic stroke and atrial fibrillation found the risk of early recurrent stroke in the placebo group over the first 7 days to be as high as 8.5%. 16 Therefore, more trials are needed, testing intravenous UFH in hyperacute stroke patients whose cardiocerebrovascular lesions are clarified by modern brain and vascular imaging. However, early initiation of UFH therapy is also known to be associated with hemorrhagic transformation and clinical worsening. 10 Because early initiation of UFH therapy can be a double-edged sword, a method of intravenous UFH delivery that is least likely to produce complications, and most likely to improve the outcome, is necessary in the acute stages. A dosing regimen that can rapidly achieve a therapeutic APTT while avoiding subtherapeutic and supratherapeutic anticoagulation in the acute stages can be a solution. While stroke recurrence is associated with subtherapeutic anticoagulation, supratherapeutic anticoagulation is observed in patients with symptomatic bleeding, especially on the day of bleeding. 10 Complete anticoagulation was shown to not only prevent embolisms to the brain 17 but also reduce the severity of stroke occurring during treatment of patients with atrial fibrillation. 18 Furthermore, an experimental study has demonstrated that a steady plasma concentration of UFH can reduce the infarct volume after transient focal cerebral ischemia in the rat. 19 Thus, ''fine tuning'' the dose of intravenous UFH administration might favorably shift the risk-benefit ratio.
There are several weaknesses of our study that need to be discussed. First, this study was not designed to examine the efficacy of intravenous UFH in stroke or TIA. Second, our study was designed before the publication of a recent study that showed that intravenous UFH administered within the first 3 hours of the onset of the symptoms could be beneficial to stroke patients. 9 Therefore, we allowed too broad a time window ðadmission within the first 48 hoursÞ in our study. Because the purpose of our study was not to examine the efficacy of UFH, but the parameters of anticoagulation, the time window was not an important factor when our study was designed. Finally, although the success rate at 2 hours was higher in group 2 than in group 1, the success rates at 4 and 6 hours were not significantly different between the groups. At 2 hours, in other words, the initial bolus dose affected the proportion of therapeutic APTT results. However, the effects of the initial bolus dose did not last longer than this. At 4 and 6 hours, the initial infusion rate, rather than the bolus dose, may determine the proportion of therapeutic APTT results.
In conclusion, our study found that the use of the low bolus dose of UFH achieves therapeutic APTTs faster and maintains therapeutic APTTs more frequently within 6 hours of UFH treatment. Adequately powered hyperacute anticoagulation trials to determine which stroke subtypes benefit from the use of UFH are needed to establish the role of UFH in the treatment of stroke or TIA. Using the low bolus dose of UFH may reduce complication rates and improve clinical outcomes, thus favorably shifting the risk-benefit ratio in the future clinical trials.
